Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
J Natl Cancer Inst
    March 2024
  1. FUCITO LM, Palmer AM, Baldassarri SR
    A new perspective on mitigating lung cancer risks through smoking cessation and reduction.
    J Natl Cancer Inst. 2024 Mar 18:djae044. doi: 10.1093.
    >> Share

  2. NAGASAKI Y, Taki T, Nomura K, Tane K, et al
    Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Mar 8:djae053. doi: 10.1093.
    >> Share

    February 2024
  3. MOEN EL, Schmidt RO, Onega T, Brooks GA, et al
    Association between a network-based physician linchpin score and cancer patient mortality: a SEER-Medicare analysis.
    J Natl Cancer Inst. 2024;116:230-238.
    >> Share

  4. MEERNIK C, Raveendran Y, Kolarova M, Rahman F, et al
    Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review.
    J Natl Cancer Inst. 2024 Feb 6:djae026. doi: 10.1093.
    >> Share

    January 2024
  5. GUTIERREZ-TORRES DS, Kim S, Albanes D, Weinstein SJ, et al
    Changes in smoking use and subsequent lung cancer risk in the ATBC study.
    J Natl Cancer Inst. 2024 Jan 25:djae012. doi: 10.1093.
    >> Share

    December 2023
  6. SHIELS MS, Graubard BI, McNeel TS, Kahle L, et al
    Trends in smoking-attributable and smoking-unrelated lung cancer death rates in the U.S., 1991-2018.
    J Natl Cancer Inst. 2023 Dec 9:djad256. doi: 10.1093.
    >> Share

  7. BILLINGY NE, Tromp VNMF, Aaronson NK, Hoek RJA, et al
    Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial.
    J Natl Cancer Inst. 2023;115:1515-1525.
    >> Share

  8. ZUMSTEG ZS, Luu M, Rosenberg PS, Elrod JK, et al
    Global epidemiologic patterns of oropharyngeal cancer incidence trends.
    J Natl Cancer Inst. 2023;115:1544-1554.
    >> Share

    November 2023
  9. LEHRER S, Rheinstein PH
    Re: Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancers.
    J Natl Cancer Inst. 2023;115:1427-1428.
    >> Share

  10. LU K, Wang HC, Tu YC, Chang CC, et al
    Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer.
    J Natl Cancer Inst. 2023;115:1383-1391.
    >> Share

  11. EVANS JV, Suman S, Goruganthu MUL, Tchekneva EE, et al
    Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.
    J Natl Cancer Inst. 2023;115:1404-1419.
    >> Share

    September 2023
  12. KHODAYARI MOEZ E, Warkentin MT, Brhane Y, Lam S, et al
    Circulating proteome for pulmonary nodule malignancy.
    J Natl Cancer Inst. 2023;115:1060-1070.
    >> Share

    August 2023
  13. RAPHAEL J, Richard L, Lam M, Blanchette P, et al
    Early mortality in patients with cancer treated with immune checkpoint inhibitors in routine practice.
    J Natl Cancer Inst. 2023;115:949-961.
    >> Share

    July 2023
  14. CHANG A, Flores RM, Taioli E
    Unequal Racial Distribution of Immunotherapy for Late-Stage Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2023 Jul 8:djad132. doi: 10.1093.
    >> Share

    June 2023
  15. MILANO MT, Salama JK, Chmura SJ
    Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?
    J Natl Cancer Inst. 2023;115:605-607.
    >> Share

  16. WANG XS, Bai YF, Verma V, Yu RL, et al
    Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2023;115:742-748.
    >> Share

  17. FENG X, Wu WY, Onwuka JU, Haider Z, et al
    Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools.
    J Natl Cancer Inst. 2023 Jun 1:djad071. doi: 10.1093.
    >> Share

    May 2023
  18. CARROLL NM, Burnett-Hartman AN, Rendle KA, Neslund-Dudas CM, et al
    Smoking status and the association between patient-level factors and survival among lung cancer patients.
    J Natl Cancer Inst. 2023 May 25:djad098. doi: 10.1093.
    >> Share


  19. Correction to: Randomized trial of First-Line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung cancer.
    J Natl Cancer Inst. 2023 May 18:djad084. doi: 10.1093.
    >> Share

  20. RUSTHOVEN CG, Staley AW, Gao D, Yomo S, et al
    Comparison of First-Line Radiosurgery for Small-Cell and Non-Small Cell Lung Cancer Brain Metastases (Cross-FIRE).
    J Natl Cancer Inst. 2023 May 4:djad073. doi: 10.1093.
    >> Share

    April 2023
  21. UNGER JM, Qian L, Redman MW, Tavernier SS, et al
    Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
    J Natl Cancer Inst. 2023;115:437-446.
    >> Share

  22. OH DL, Schumacher K, Yang J, Wang K, et al
    Disparities in cancer incidence by rurality in California.
    J Natl Cancer Inst. 2023;115:385-393.
    >> Share

    February 2023
  23. SELBY K, Sedki M, Levine E, Kamineni A, et al
    Test performance metrics for breast, cervical, colon and lung cancer screening: a systematic review.
    J Natl Cancer Inst. 2023 Feb 8:djad028. doi: 10.1093.
    >> Share

    December 2022
  24. SIRUFO MM, Ginaldi L, De Martinis M
    RE: Sociodemographic Survival Disparities for Lung Cancer in the United States, 2000-2016.
    J Natl Cancer Inst. 2022 Dec 19:djac235. doi: 10.1093.
    >> Share

    November 2022
  25. HEIDEN BT, Eaton DB, Chang SH, Yan Y, et al
    Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer.
    J Natl Cancer Inst. 2022 Nov 29:djac208. doi: 10.1093.
    >> Share

  26. LI M, Liao K, Chen AJ, Cascone T, et al
    Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer.
    J Natl Cancer Inst. 2022 Nov 8. pii: 6809139. doi: 10.1093.
    >> Share

  27. DI FEDERICO A, De Giglio A, Gelsomino F, Sperandi F, et al
    Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis.
    J Natl Cancer Inst. 2022 Nov 2. pii: 6794208. doi: 10.1093.
    >> Share

    October 2022
  28. YOU S, Kim M, Hoi XP, Lee YC, et al
    Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy.
    J Natl Cancer Inst. 2022;114:1380-1391.
    >> Share

    September 2022
  29. WARKENTIN MT, Tammemagi MC, Espin-Garcia O, Budhathoki S, et al
    Lung Cancer Absolute Risk Models for Mortality in Asian Population using China Kadoorie Biobank.
    J Natl Cancer Inst. 2022 Sep 9. pii: 6694851. doi: 10.1093.
    >> Share

  30. PELLINEN T, Paavolainen L, Martin-Bernabe A, Papatella Araujo R, et al
    Fibroblast subsets in non-small cell lung cancer: associations with survival, mutations, and immune features.
    J Natl Cancer Inst. 2022 Sep 9. pii: 6694853. doi: 10.1093.
    >> Share

    August 2022
  31. SEDANI AE, Davis OC, Clifton SC, Campbell JE, et al
    Facilitators and Barriers to Implementation of Lung Cancer Screening: A Framework Driven Systematic Review.
    J Natl Cancer Inst. 2022 Aug 22. pii: 6673083. doi: 10.1093.
    >> Share

  32. VOGTMANN E, Hua X, Yu G, Purandare V, et al
    The oral microbiome and lung cancer risk: An analysis of 3 prospective cohort studies.
    J Natl Cancer Inst. 2022 Aug 5. pii: 6656358. doi: 10.1093.
    >> Share

    July 2022
  33. BROUWER AF, Engle JM, Jeon J, Meza R, et al
    Sociodemographic survival disparities for lung cancer in the United States, 2000-2016.
    J Natl Cancer Inst. 2022 Jul 22. pii: 6648464. doi: 10.1093.
    >> Share

  34. TAYLOR KL, Williams RM, Li T, Luta G, et al
    A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting.
    J Natl Cancer Inst. 2022 Jul 12. pii: 6633937. doi: 10.1093.
    >> Share

    June 2022
  35. CASTILHO JL, Bian A, Jenkins CA, Shepherd BE, et al
    CD4/CD8 Ratio and Cancer Risk Among Adults With HIV.
    J Natl Cancer Inst. 2022;114:854-862.
    >> Share

    May 2022
  36. GABRIEL AAG, Atkins JR, Penha RCC, Smith-Byrne K, et al
    Genetic analysis of lung cancer and the germline impact on somatic mutation burden.
    J Natl Cancer Inst. 2022 May 2. pii: 6576636. doi: 10.1093.
    >> Share

    April 2022

  37. Expression of Concern to: Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2022 Apr 1. pii: 6561908. doi: 10.1093.
    >> Share

    February 2022
  38. TANAKA I, Dayde D, Tai MC, Mori H, et al
    SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.
    J Natl Cancer Inst. 2022;114:290-301.
    >> Share

    December 2021
  39. CHOI E, Luo SJ, Aredo JV, Backhus LM, et al
    The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.
    J Natl Cancer Inst. 2021 Dec 10. pii: 6459177. doi: 10.1093.
    >> Share

    November 2021
  40. ISLAMI F, Ward EM, Sung H, Cronin KA, et al
    Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.
    J Natl Cancer Inst. 2021;113:1648-1669.
    >> Share

  41. GAVRIELATOU N, Shafi S, Gaule P, Rimm DL, et al
    PD-L1 Expression Scoring: Noninterchangeable, Noninterpretable, Neither, or Both.
    J Natl Cancer Inst. 2021;113:1613-1614.
    >> Share

    August 2021
  42. HOPKINS AM, Kichenadasse G, Logan JM, Rowland A, et al
    RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2021 Aug 27. pii: 6358733. doi: 10.1093.
    >> Share

  43. ZHAO W, Zhu B, Hutchinson A, Pesatori AC, et al
    Clinical Implications of Inter- and Intra-Tumor Heterogeneity of Immune Cell Markers in Lung Cancer.
    J Natl Cancer Inst. 2021 Aug 17. pii: 6353611. doi: 10.1093.
    >> Share

  44. DEROUEN MC, Canchola AJ, Thompson CA, Jin A, et al
    Incidence of Lung Cancer Among Never-Smoking Asian American, Native Hawaiian, and Pacific Islander Females.
    J Natl Cancer Inst. 2021 Aug 4. pii: 6338453. doi: 10.1093.
    >> Share

    July 2021
  45. CHOI E, Sanyal N, Ding VY, Gardner RM, et al
    Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer.
    J Natl Cancer Inst. 2021 Jul 13. pii: 6320070. doi: 10.1093.
    >> Share

    June 2021
  46. WANG X, Ricciuti B, Alessi JV, Nguyen T, et al
    Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2021 Jun 11. pii: 6296846. doi: 10.1093.
    >> Share

    April 2021
  47. VERHOEVEN DC, Chollette V, Lazzara EH, Shuffler ML, et al
    The Anatomy and Physiology of Teaming in Cancer Care Delivery: A Conceptual Framework.
    J Natl Cancer Inst. 2021;113:360-370.
    >> Share

    December 2020
  48. MITCHELL AP, Bach PB
    Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care.
    J Natl Cancer Inst. 2020;112:1177-1178.
    >> Share

    July 2020
  49. TAKVORIAN SU, Balogh E, Nass S, Valentin VL, et al
    Developing and Sustaining an Effective and Resilient Oncology Careforce: Opportunities for Action.
    J Natl Cancer Inst. 2020;112:663-670.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016